Madrigal Pharmaceuticals Inc
$ 527.11
-0.92%
20 Apr - close price
- Market Cap 12,204,522,000 USD
- Current Price $ 527.11
- High / Low $ 530.66 / 521.92
- Stock P/E N/A
- Book Value 26.39
- EPS -12.87
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.43 %
- 52 Week High 615.00
- 52 Week Low 265.00
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Analyst Target Price
$672.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-10-31 | 2024-08-07 | 2024-05-07 | 2024-02-28 | 2023-11-06 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -2.57 | -4.9555 | -1.9 | -3.32 | -2.71 | -4.92 | -7.1 | -7.38 | -5.68 | -5.34 | -4.69 | -4.23 |
| Estimated EPS | -0.6039 | -3.36 | -3.63 | -6.28 | -4.1246 | -6.91 | -7.53 | -6.28 | -5.28 | -4.93 | -4.58 | -4.94 |
| Surprise | -1.9661 | -1.5955 | 1.73 | 2.96 | 1.4146 | 1.99 | 0.43 | -1.1 | -0.4 | -0.41 | -0.11 | 0.71 |
| Surprise Percentage | -325.5671% | -47.4851% | 47.6584% | 47.1338% | 34.2967% | 28.7988% | 5.7105% | -17.5159% | -7.5758% | -8.3164% | -2.4017% | 14.3725% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -3.62 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDGL
2026-04-17 15:10:06
Madrigal Pharmaceuticals' stock surged following its Q2 earnings report, driven by exceptional sales of its MASH drug, Rezdiffra. The company reported a significant revenue beat at $24.2 million, far exceeding analyst expectations, and a narrower-than-anticipated net loss. This strong performance indicates a positive market reception and robust demand for Rezdiffra.
2026-04-15 19:40:19
Madrigal Pharmaceuticals (MDGL) stock surged 12.3% in the last trading session, outperforming the S&P 500's 1.7% gain. Despite this recent increase, analysts have a mixed outlook on the stock, with an average price target that suggests a potential downside, yet recent earnings estimates have been revised upwards. Investors should consider the company's fundamentals and future growth prospects in light of both positive and negative indicators.
2026-04-14 20:10:37
Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted equity awards to 20 new non-executive employees on April 1, 2026, as part of their 2025 Inducement Plan. These awards, totaling 8,079 time-based restricted stock units, will vest over four years to incentivize the hires. The move aligns with Nasdaq Listing Rule 5635(c)(4), supporting the company's focus on developing treatments for metabolic dysfunction-associated steatohepatitis.
2026-04-11 07:39:04
Madrigal Pharmaceuticals announced that it granted equity awards to 20 new non-executive employees on April 1, 2026, under its 2025 Inducement Plan. These equity inducement awards, totaling 8,079 time-based restricted stock units, were approved in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize new hires. The awards vest in four equal installments over four years, contingent on continued employment.
2026-04-10 12:39:24
Madrigal Pharmaceuticals (MDGL) has seen significant share price volatility but appears undervalued based on two valuation methods. A Discounted Cash Flow (DCF) analysis estimates the stock to be 71.3% undervalued at approximately $1,809.70 per share compared to its current price of $519.75. Additionally, the P/S ratio suggests the shares are trading below their fair value.
2026-04-09 21:09:44
Madrigal Pharmaceuticals (MDGL) has seen significant share price volatility, with a 65.6% return over the past year. Despite recent declines, two valuation models, Discounted Cash Flow (DCF) and Price to Sales (P/S) ratio, suggest the stock is undervalued. The DCF analysis indicates a potential intrinsic value of $1,809.70 per share, significantly higher than its current trading price of around $519.75.
